1	COVID-19 mRNA vaccines induce robust levels of IgG but limited amounts of IgA
2	within the oronasopharynx of young children
3	
4	Ying Tang <sup>1,2,*</sup> , Brittany P. Boribong <sup>2,3,4,*</sup> , Zoe N. Swank <sup>2,5,6</sup> , Melina Demokritou <sup>3</sup> , Maria A.F.
5	Luban <sup>3</sup> , Alessio Fasano <sup>2,3,4</sup> , Michelle Du <sup>7</sup> , Rebecca L. Wolf <sup>7</sup> , Joseph Griffiths <sup>7</sup> , John Shultz <sup>7</sup> , Ella
6	Borberg <sup>2,5,6</sup> , Sujata Chalise <sup>2,5,6</sup> , Wanda I. Gonzalez <sup>2,4</sup> , David R. Walt <sup>2,5,6</sup> , Lael M. Yonker <sup>2,3,4,**,#</sup> ,
7	and Bruce H. Horwitz <sup>1,2,7,**,#</sup>
8	
9	<sup>1</sup> Division of Gastroenterology, Hepatology, and Nutrition, Boston Children's Hospital, Boston,
10	MA 02115, USA
11	<sup>2</sup> Harvard Medical School, Boston, MA 02115, USA
12	<sup>3</sup> Mucosal Immunology and Biology Research Center, Massachusetts General Hospital, Boston,
13	MA 02114, USA
14	<sup>4</sup> Department of Pediatrics, Massachusetts General Hospital, Boston, MA 02114, USA
15	<sup>5</sup> Department of Pathology, Brigham and Women's Hospital, Boston, MA 02115, USA
16	<sup>6</sup> Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02215,
17	USA
18	<sup>7</sup> Division of Emergency Medicine, Boston Children's Hospital, Boston, MA 02115, USA
19	*These first authors contributed equally
20	**These senior authors contributed equally
21	<sup>#</sup> Correspondence: lyonker@mgh.harvard.edu (L.M.Y) and <u>bruce.horwitz@childrens.harvard.edu</u>
22	(B.H.H.)
23	
24	Key points
25	Current COVID-19 mRNA vaccine induces salivary and nasal SARS-CoV-2 specific IgG but
26	not IgA production in children under 5 years of age
27	Mucosal anti-spike IgA is important for immune complex-mediated neutrophil extracellular
~ ~	the state of the state of CARO On V(C) is the structure

trap formation against SARS-CoV-2 in the airway

## 29 Abstract

- 30 Background. Understanding antibody responses to SARS-CoV-2 vaccination is crucial for
- refining COVID-19 immunization strategies. Generation of mucosal immune responses,
- 32 including mucosal IgA, could be of potential benefit to vaccine efficacy, yet limited evidence
- exists regarding the production of mucosal antibodies following the administration of current
- 34 mRNA vaccines to young children.
- 35 **Methods.** We measured the levels of antibodies against SARS-CoV-2 from a cohort of children
- 36 under 5 years of age undergoing SARS-CoV-2 mRNA vaccination (serially collected, matched
- 37 serum and saliva samples, N=116) or on convenience samples of children under 5 years of age
- 38 presenting to a pediatric emergency department (nasal swabs, N=103). Further, we assessed
- 39 salivary and nasal samples for the ability to induce SARS-CoV-2 spike-mediated neutrophil
- 40 extracellular traps (NET) formation.
- 41 **Results.** Longitudinal analysis of post-vaccine responses in saliva revealed the induction of
- 42 SARS-CoV-2 specific IgG but not IgA. Similarly, SARS-CoV-2 specific IgA was only observed in
- 43 nasal samples obtained from previously infected children with or without vaccination, but not in
- 44 vaccinated children without a history of infection. In addition, oronasopharyngeal samples
- 45 obtained from children with prior infection were able to trigger enhanced spike-mediated NET
- 46 formation, and IgA played a key role in driving this process.
- 47 **Conclusions.** Despite the induction of specific IgG in the oronasal mucosa, current
- 48 intramuscular vaccines have limited ability to generate mucosal IgA in young children. These
- 49 results confirm the independence of mucosal IgA responses from systemic humoral responses
- 50 following mRNA vaccination and suggest potential future vaccination strategies for enhancing
- 51 mucosal protection in this young age group.

#### 52 Major Article

#### 53 INTRODUCTION

54 While there is clear evidence that current COVID-19 mRNA vaccines induce robust and protective systemic immune responses, the ability of these vaccines to induce mucosal 55 56 responses is less understood. Mucosal immune responses may provide additive benefits potentially important for limiting transmission and increasing effectiveness against severe 57 58 disease [1]. It has been demonstrated in animal models that targeted nasal immunization, but 59 not intramuscular immunization, with ChAd-SARS-CoV-2 induces robust mucosal anti-IgA 60 responses with near sterilizing immunity, suggesting a role for mucosal IgA responses in preventing SARS-CoV-2 infection and transmission [2]. Moreover, nasal SARS-CoV-2 specific 61 antibody responses have been associated with lower viral loads and milder systemic symptoms 62 63 of COVID-19 [3]. Studies on adults revealed that prior infection induces significantly higher mucosal IgA than mRNA vaccination [4-6], underscoring the limited impact of intramuscular 64 65 vaccination on the induction of mucosal SARS-CoV-2 specific IgA in adults [7]. Young children have developing immune systems with significantly reduced capacity to generate circulating 66 anti-SARS-CoV-2 IgA following vaccination as compared to adults [8]. However, studies 67 68 examining mucosal IgA responses in children following SARS-CoV2 mRNA vaccinations are 69 limited. 70 Here, we longitudinally evaluated both serological and salivary antibody responses in a 71 cohort of children under 5 years of age with and without a prior history of SARS-CoV-2 infection 72 following primary mRNA vaccination. We also compared antibody levels in nasal samples 73 obtained from children with a history of COVID-19, those with a prior history of vaccination,

those with both infection and vaccination, or those with neither. Additionally, we explored the

ability of spike-specific mucosal antibodies to induce neutrophil activation. Our results reveal

that while mRNA vaccination can generate robust systemic and mucosal IgG production,

vaccination alone has a limited ability to induce oronasopharyngeal IgA, nor does it boost

78 mucosal IgA levels induced by prior SARS-CoV-2 infection. Further, our data also suggest that

79 IgA produced in response to prior SARS-CoV-2 infection is a key driver of anti-SARS-CoV-2

80 antibody-induced neutrophilic activation.

#### 81 METHODS

## 82 Study Design

83 Longitudinal cohort. Children aged 5 years or younger undergoing a COVID-19 mRNA vaccination series were enrolled in this study. Informed consent was obtained from parents/legal 84 85 guardians. The IRB of Massachusetts General Hospital gave ethical approval for this work. SARS-CoV-2 infection history and demographic information were obtained from electronic 86 87 medical records. Samples from individuals who were infected during the vaccine series were excluded from this analysis. All subjects received either Pfizer (BNT162b2) or Moderna (mRNA-88 89 173) for primary vaccine doses. Samples were collected before vaccination (V0) and 2-4 weeks 90 following the first, the second, and (in those receiving the Pfizer vaccine) the third vaccine doses (V1, V2, V3, respectively). Saliva was collected by holding a SalivaBio swab (Salimetrics) under 91 92 the tongue for 2 minutes or until fully saturated. The saturated swab was then placed in the upper chamber of the Swab Storage Tube (Salimetrics) and centrifuged at 450g at 4°C for 15 93 94 minutes. Saliva was collected, aliquoted, and stored at -80°C until use. Blood was collected via venipuncture into serum separation tubes (BD) or by a microneedle capillary blood collection 95 device. Serum was collected, aliquoted, and stored at -80°C until use. 96 97 Emergency department convenience cohort. Children under 5 years old presenting to the 98 Emergency Department at Boston Children's Hospital (BCH) were enrolled in this study. Written

informed consent was acquired from parents/legal guardians. The IRB of Boston Children's
Hospital gave ethical approval for this work. Participants with a current positive SARS-CoV-2
PCR test were excluded from this study, and their vaccination status, prior infection status as
well as demographic information were obtained from a parental questionnaire. Following
completion of clinically indicated viral testing employing a nasopharyngeal swab, discarded viral
transport medium (VTM) was retrieved and stored at -80°C until use.

## 105 Simoa anti-SARS-CoV-2 antibody measurements

106 Saliva samples were diluted 64-fold in StartingBlockTM T20 blocking buffer (Thermo Fisher 107 Scientific) containing protease inhibitors (HaltTM Protease Inhibitor Cocktail, Thermo Fisher Scientific). Single molecule array (Simoa) assays were then used to measure anti-S1, anti-RBD, 108 109 anti-spike, and anti-nucleocapsid antibodies, as previously described [9]. Briefly, using an HD-X 110 Analyzer (Quanterix Corporation, Billerica MA), the diluted samples were incubated with dyeencoded magnetic beads coated with recombinant proteins. The beads were washed and 111 resuspended in a solution of biotinylated anti-human-IgG antibody. The beads were then 112 113 washed again and resuspended in a solution of streptavidin-conjugated  $\beta$ -galactosidase. Lastly, 114 the beads were resuspended in a solution of resorufin  $\beta$ -D-galactopyranoside and loaded into a

- 115 microwell array for imaging. Average enzymes per bead (AEB) values were calculated by the
- 116 HD-X software and normalized between runs using a COVID-19 positive serum standard.

### 117 Nasal antibody detection

- 118 VTM samples were thawed and centrifuged at 3000g for 5 mins. SARS-CoV-2 anti-S1, -S2, -
- 119 RBD and -Nucleocapsid IgG and IgA levels were determined using MILLIPLEX® SARS-CoV-2
- 120 Antigen Panel 1 IgG assay (Millipore Sigma, Cat. No. HC19SERG1-85K) and MILLIPLEX®
- 121 SARS-CoV-2 Antigen Panel 1 IgA assay (Millipore Sigma, Cat. No. HC19SERA1-85K),
- 122 respectively. The protocol was followed as described by the manufacturer, except 50µL/well of
- 123 undiluted VTM samples were used as the starting material, and an additional fixation step with
- 124 4% PFA was included following the final wash. Samples were analyzed using the Luminex<sup>™</sup>
- 125 200<sup>™</sup> system. All samples were measured in duplicate, and control beads were used for
- 126 normalization.

## 127 NETosis assay

128 The NETosis assay was performed as previously described [10]. Briefly, microfluidic devices

- 129 were primed with RPMI media with no FBS. Neutrophils were isolated from healthy donors
- 130 using the Easysep Direct Neutrophil Isolation Kit (STEMCELL Technologies). Isolated
- neutrophils were stained with 32 µM Hoeschst 3342 dye and mixed with SYTOX green (final
- 132 concentration 2  $\mu$ M). Stained neutrophils were stimulated with either pooled saliva samples or
- 133 individual samples of VTM in the presence or absence of spike-coated NeutrAvidin beads. The
- cell suspensions were then loaded into a microfluidic device and imaged with brightfield, FITC,
- and DAPI fields every 10 minutes for 6 hours. NETosis was then quantified using FIJI and the
- 136 TrackMate plugin.

## 137 Statistical analysis

138 Two-tailed Mann-Whitney U tests were conducted to identify significant differences between

- 139 groups in GraphPad Prism version 10.1. Statistical significance is defined as \*p < 0.05, \*\*p <
- 140 0.01, \*\*\*p < 0.001, and \*\*\*\*p < 0.0001.

#### 141 **RESULTS**

## 142 mRNA vaccination fails to induce spike-specific IgA in saliva.

143 To quantify mucosal and serologic antibody responses generated by COVID-19 mRNA vaccination, we evaluated saliva and blood samples collected from healthy children with and 144 145 without prior history of COVID-19 based on their medical records (demographics shown in Table 1). Matched serum and saliva samples were collected longitudinally prior to vaccination and 4 146 147 weeks following each vaccine dose (Figure 1A). Participants were divided into two groups: "Vaccine-only" (no prior infection) and "Vaccine/Infection" (with prior SARS-CoV-2 infection). 148 149 Consistent with the prior history, serum anti-nucleocapsid IgG levels were significantly higher in 150 the Vaccine/Infection group than in the Vaccine-only group (Figure 1B). As expected, prior to vaccination (baseline, V0), we found significantly higher levels of anti-spike IgG and IgA in the 151 152 serum of participants in the Vaccine/Infection group than in the Vaccine-only group (Figure 1C). 153 Anti-spike IgG and IgA were significantly higher in serum collected following the completion of 154 vaccination (V2 or V3) than prior to vaccination in both groups, although levels of both IgG and IgA remained higher in the Vaccine/Infection group than in the Vaccine-only group throughout 155 156 the time course (Figure 1C). Similar patterns were observed for both anti-S1 and anti-RBD 157 responses in serum samples (Figure S1).

158 Similar to responses in the serum, prior to vaccination, salivary anti-spike IgG was 159 significantly higher in the Vaccine/Infection group than in the Vaccination-only group, and was 160 significantly higher following completion of vaccination than prior to vaccination in both groups 161 (Figure 1D, left). Likewise, salivary levels of anti-spike IgG remained significantly higher in the 162 Vaccine/Infection group than in the Vaccine-only group throughout the time course, and similar 163 patterns were observed for salivary anti-S1 and anti-RBD IgG (Figure S2A). While levels of antispike IgA in the saliva at baseline were also significantly higher in the Vaccine/Infection group 164 165 than in the Vaccine-only group, we were unable to detect a significant increase in levels of anti-166 spike IqA in either group following vaccination (Figure 1D, right). Small but statistically 167 significant increases in the levels of anti-S1 IgA but not in anti-RBD IgA were observed in the Vaccine-only group following vaccination (Figure S2B). Taken together, these observations 168 169 suggest that the ability of COVID-19 mRNA vaccination to induce salivary IgA is guite limited. 170

171 mRNA vaccination fails to induce anti-spike IgA in the nasal mucosa

172 To further evaluate nasopharyngeal antibody levels following mRNA vaccination and/or

173 SARS-CoV-2 infection, we collected viral transport media (VTM) samples used for testing of

174 material collected on nasopharyngeal swabs obtained from a convenience cohort of children

175 under 5 years of age presenting to a pediatric emergency department for evaluation of 176 respiratory symptoms (demographics shown in Table 2). Children who tested positive for acute 177 SARS-CoV-2 infection were excluded from this study. Children were categorized into 4 groups based on parental recall of COVID-19 mRNA vaccination and evidence of prior SARS-CoV-2 178 179 infection (presence of anti-nucleocapsid IgG in the VTM): No history of vaccination or evidence 180 of SARS-CoV-2 infection ("Negative"), history of vaccination only ("Vaccine-only"), evidence for 181 SARS-CoV-2 infection only ("Prior Infection"), and a history of both ("Vaccine/Infection"). We 182 found that SARS-CoV-2-specific IgG levels were significantly higher in the Vaccine-only. 183 Vaccine/Infection, and Prior Infection groups compared to the Negative group (Figure 2B), 184 suggesting effective induction of SARS-CoV-2 specific IgG within the nasal mucosa by either vaccination or natural infection. Notably, levels of nasal IgG were significantly higher in children 185 186 who were both vaccinated and had a prior SARS-CoV-2 infection compared to all other groups, indicating that COVID-19 mRNA vaccination likely boosts nasal IgG levels in participants 187 188 previously infected with SARS-CoV-2. 189 In contrast, nasal anti-S1, anti-S2, and anti-RBD IgA levels were significantly higher in the 190 Vaccine/Infection and Prior Infection groups than in both the Negative and Vaccine-only groups, 191 and we were unable to detect a significant difference in anti-S1 or anti-RBD IgA levels between

- the Vaccine-only group and the Negative group, nor between the Vaccine/Infection group and
- the Prior infection group (Figure 2C). We did detect a small but significant increase in anti-S2
  IgA levels between the Vaccine-only group and the Negative group, although we did not
  appreciate a significant increase in anti-S2 IgA between the Vaccine/Infection group and the
  Prior Infection group. Similar to results with saliva, these results indicate that despite the ability
  to induce mucosal IgG, the ability of COVID-19 mRNA vaccination to induce SARS-CoV-2
- 198 specific IgA in the nasal mucosa is quite limited.
- 199

# SARS-CoV-2 specific salivary and nasal antibodies trigger extensive spike-mediated neutrophil activation

Neutrophils are abundant in the nasal mucosa of healthy children, and exhibit a more activated phenotype than neutrophils in the adult nose following SARS-CoV-2 infection [11]. However, whether SARS-CoV-2 specific antibodies in the oronasopharynx have the ability to activate neutrophils following antigen exposure is not fully defined, and further, the role of mucosal IgA in this process remains to be determined. To examine whether mucosal antibodies induced by vaccination and/or natural infection have the ability to activate neutrophils and induce the formation of neutrophil extracellular traps (NET), we pooled saliva samples from

209 healthy children with completed vaccine doses in the following groups: "Negative" (no prior 210 infection or vaccination), "Vaccine-only" (vaccinated individuals without history of COVID-19) 211 and "Vaccine/Infection" (vaccinated individuals with prior infection) (N=4 samples per pool) to obtain sufficient volumes of saliva to evaluate NET formation. We then mixed these pooled 212 213 saliva samples with spike protein-coated beads to induce immune complex formation and added 214 these mixtures to neutrophils isolated from four healthy individuals. We assessed neutrophil 215 activation by quantification of the percentage of neutrophils that undergo NETosis (Figure 3A). 216 None of the sample pools induced NETosis in the absence of spike protein, but we observed 217 significant increases in NETosis following the addition of spike protein to the Vaccine-only pool 218 and the Vaccine/Infection pool, but not from the Negative pool (Figure 3B), consistent with the 219 presence of antibodies with the ability to induce anti-spike immune complexes in these pools. 220 Interestingly, the level of NETosis was higher in the Vaccine/Infection pool than in the Vaccineonly pool, likely reflecting the higher levels of salivary anti-SARS-CoV-2 antibodies, although the 221 222 analysis of a single pool limits our ability to evaluate significance across pools assembled from 223 the different groups. To address this potential limitation, we compared the ability of a subset of 224 nasal samples (N=4 per group) to induce NETosis following exposure to spike protein-coated 225 beads (Figure 3C). Antibody levels for each individual sample used in this assay are shown in 226 Figure S3. The induction of NETosis was significantly higher in Vaccine-only, Vaccine/Infection, 227 and Prior Infection groups than in the Negative group, and we observed significantly higher 228 levels of NETosis in the Vaccine/Infection group than in all other groups (Figure 3D). Taken 229 together, these results confirm that higher levels of antibodies observed within the oronasal 230 mucosa of vaccinated children with a prior SARS-CoV-2 infection are associated with an 231 enhanced neutrophil activation, likely signifying functional importance.

232

#### 233 Spike-specific IgA in saliva acts as a key inducer of neutrophil activation

234 To better understand which subclass of antibodies drives the NETosis observed in salivary 235 samples, we depleted either IgG, IgA, or both from pooled saliva samples and evaluated neutrophil activation following the addition of spike protein-coated beads (Figure 4A). We found 236 237 that depletion of either IgG or IgA from the Vaccine-only or Vaccine/Infection pools significantly 238 inhibited NETosis and that NETosis was eliminated by depletion of both IgG and IgA (Figure 4B and 4C). Thus, both IgG and IgA contribute to the ability of oronasal mucosal antibodies to 239 240 induce SARS-CoV-2 specific neutrophil activation in children exposed and/or immunized to the 241 virus. One inconsistency we noted is that IgA depletion in Vaccine-only saliva pool significantly 242 inhibited the neutrophil NET formation, even though we did not observe significant induction of

- 243 mucosal IgA by vaccination alone. We believe that a non-specific ability of IgA in saliva to
- induce NET formation is unlikely, given that saliva from children without a history of COVID-19
- 245 did not induce NET formation prior to vaccination. Rather, we suspect that vaccination alone
- 246 does result in low levels of mucosal IgA potentially from passive transport from serum and that
- 247 we were unable to detect significant differences in levels of nasal IgA between the unvaccinated
- and vaccinated groups given our sample size limitations. Future studies with larger sample
- sizes will be necessary to definitively answer this question.

#### 250 **DISCUSSION**

251 In June 2022, the FDA granted approval for the administration of the COVID-19 mRNA 252 vaccine to children aged 6 months to 5 years, however over 95% of children have been 253 exposed to SARS-CoV-2 based on national serological surveillance testing [12]. Thus, it is 254 essential to conduct a thorough evaluation of both systemic and mucosal humoral responses 255 triggered by immunization in children under 5 years of age with and without prior infection. 256 The robust anti-spike IgG and IgA responses we observed in serum post-vaccination aligned 257 with the broader consensus regarding the efficacy of current mRNA vaccine in inducing 258 systemic immunity. In addition, we revealed that vaccination induced mucosal IgG responses in 259 children, though hybrid immunity induced the highest level of SARS-CoV-2 specific IgG. Our observation of close correlation between systemic and mucosal IgG levels is consistent with 260 261 models in which IgG accumulates in the mucosa as the result of passive transport from the circulatory system [13]. In contrast, our study highlighted the limited ability of these vaccines to 262 263 generate mucosal IgA responses, and confirms that mucosal IgA production in the oronasopharynx can be largely independent of systemic IgA responses [14]. IgA is recognized 264 265 as an important factor in mucosal immunity regarding its role in neutralizing pathogens, 266 particularly in the gastrointestinal tract and the upper airways [15]. Notably, mucosal IgA has 267 been identified as a critical antibody type protecting against SARS-CoV-2 infection [16,17] and 268 correlates with reduced viral infectivity in vitro [18]. Our findings raised questions about the 269 completeness of protection conferred by the current immunization strategies, although the exact 270 function of viral-specific mucosal IgA still requires further investigation. 271 Another crucial aspect of our study involves the exploration of mucosal antibody-induced 272 neutrophil activation, as demonstrated by the assessment of neutrophil extracellular traps 273 induced by salivary and nasal samples from infected and/or immunized individuals. Neutrophils 274 have been shown to release NETs as an antimicrobial defense at the mucosa, helping to clear 275 pathogens to prevent more severe infection and disease [19,20]. Also, children have abundant 276 neutrophils in their airways, which may contribute to the rapid viral clearance and mild disease 277 observed in children [11,21,22]. In our study, we found that vaccine and infection-induced 278 mucosal antibodies were likely generating immune complexes upon spike protein challenge, 279 resulting in enhanced NET formation. Furthermore, we identified the critical role of mucosal IgA in driving spike-mediated NETosis, suggesting the generation of SARS-CoV-2 specific mucosal 280 281 IgA is a key component for providing enhanced protection against subsequent infections. While 282 mucosal IgA immune complexes are the most potent inducer of NETs, IgG immune complexes 283 were also able to induce NETs, albeit to a lesser degree, supporting that vaccination, through

284 induction of mucosal IgG, provides some degree of mucosal protection which may contribute to 285 more rapid clearance of virus in vaccinated as compared to unvaccinated individuals [23]. 286 Vaccination in previously infected individuals provided the most abundant SARS-CoV-2 specific 287 IgG, emphasizing the potential importance of continued vaccination efforts in this population. 288 Our study was limited by a relatively small sample size, however, we overcame numerous challenges in obtaining blood and mucosal samples from young pediatric cohorts with low rates 289 290 of vaccination. Thus, this sized cohort is substantial enough to offer meaningful insights. Further, we utilized non-invasive samples such as saliva and nasopharyngeal swabs to demonstrate 291 292 how mucosal immunity compared with systemic immunity. 293 In conclusion, our study confirms the ability of COVID-19 mRNA vaccines to induce mucosal 294 in addition to systemic IgG in previously uninfected young children. However, the limited 295 generation of mucosal IgA responses following vaccination underscores a potential area for improvement in current vaccination strategies for this specific demographic. Further research is 296 297 warranted to explore alternative vaccine formulations or strategies that may enhance mucosal

immunity in young children, contributing to more comprehensive protection against SARS-CoV-

299 **2**.

# 300 FUNDING

- 301 We acknowledge funding from NIH (NHLBI 5K08HL143183 to L.M.Y.), Massachusetts General
- 302 Hospital Department of Pediatrics (L.M.Y.), Boston Children's Hospital Department of Pediatrics
- 303 (B.H.H.), and the Chan-Zuckerberg Initiative (B.H.H.).
- 304

# 305 ACKNOWLEDGEMENT

- 306 Study design/funding: B.H.H., L.M.Y.; Data acquisition and analysis: Y.T., B.P.B., Z.N.S., E.B.,
- 307 S.C.; Patient consent and sample collection: W.I.G., M.D., M.A.F.L., A.F., M.D., R.L.W., J.G.,
- J.S., Y.T.; Manuscript writing: Y.T.; Figure generation: Y.T., B.P.B.; Supervision: D.R.W., B.H.H.,
- L.M.Y.; All authors reviewed and approved the final version of the manuscript.
- 310
- 311 We express extreme gratitude to all of the young children and families who participated in our
- 312 study.
- 313

# 314 CONFLICT OF INTEREST

- 315 David Walt has a financial interest in Quanterix Corporation, a company that develops an ultra-
- 316 sensitive digital immunoassay platform. He is an inventor of the Simoa technology, a founder of
- the company, and also serves on its Board of Directors. Dr. Walt's interests were reviewed and
- are managed by Brigham and Women's Hospital and Partners Healthcare in accordance with
- 319 their conflict of interest policies.





323 (A) Schematic overview of study design and sample collection timeline. (B) Serum anti-

nucleocapsid IgG level indicates prior SARS-CoV-2 infection status. Anti-nucleocapsid IgG are

shown for groups with and without a prior history of COVID-19. (C) Serum anti-spike IgG (left)

and IgA (right) levels are shown. Differences between groups are shown as black asterisks.

327 Differences between time points within groups are shown as blue or orange asterisks. Error bar

represents the mean value and the standard deviation. Two-tailed Mann-Whitney U tests were

performed between individual groups, and statistical significance is defined as \*p < 0.05, \*\*p < 0.05

330 0.01, \*\*\*p < 0.001, and \*\*\*\*p < 0.0001.



**Figure 2. SARS-CoV-2 mRNA vaccination fails to induce anti-spike IgA in the nasal** 

334 **mucosa**.

(A) Schematic overview of study design and experimental procedures. (B-C) Nasal anti-S1, -S2,

- -RBD, and -Nucleocapsid IgG (B) and IgA (C) levels were plotted, and comparisons among four
- 337 groups were conducted. Error bar represents the mean value and the standard deviation. Two-

tailed Mann-Whitney U tests were performed, and statistical significance is defined as \*p < 0.05,

339 \*\*p < 0.01, \*\*\*p < 0.001, and \*\*\*\*p < 0.0001.



342 Figure 3. SARS-CoV-2 specific salivary and nasal antibodies trigger extensive spike-

# 343 mediated neutrophil activation.

(A) Schematic overview of spike-mediated NETosis assay using saliva pools. (B) Comparison of

345 %NETosis in the presence (white bars) or absence (gray bars) of spike-coated beads in the

Negative, Vaccine-only, and Vaccine/Infection pools. **(C)** Schematic overview of spike-specific

347 NETosis assay using individual nasal samples (N=4 per group). (D) Percent NETosis of

neutrophils stimulated by spike-coated beads with nasal samples from Negative, Vaccine-only,

349 Vaccine/Infection, and Prior Infection groups. Error bar represents the mean value and the

standard deviation. Two-tailed Mann-Whitney U tests were performed, and statistical

351 significance is defined as \*p < 0.05.



353

354 Figure 4. Depletion of mucosal antibodies interferes with the neutrophil activation

induced by saliva pools from individuals in the Vaccine-only and Vaccine/Infection group.

(A) Schematic overview of antibody depletion assay in salivary samples. (B-C) End-point

357 percentage of NETs released from neutrophils stimulated with saliva from the Vaccine-only pool

(B) and the Vaccine/Infection pool (C) following depletion of IgG, IgA, or both IgG and IgA. Black

dots represent NETs released from neutrophils stimulated with the Negative saliva pool in the

360 presence of spike-coated beads. Error bar represents the mean value and the standard

361 deviation. Two-tailed Mann-Whitney U tests were performed, and statistical significance is

362 defined as \*p < 0.05.

363



367 anti-RBD (right) IgA levels are shown. Differences between groups are shown as black

368 asterisks. Differences between time points within groups are shown as blue or orange asterisks.

369 Error bar represents the mean value and the standard deviation. Two-tailed Mann-Whitney U

tests were performed, and statistical significance is defined as \*p < 0.05, \*\*p < 0.01, \*\*\*p <

371 0.001, and \*\*\*\*p < 0.0001.

372

364

365

366



379 Error bar represents the mean value and the standard deviation. Two-tailed Mann-Whitney U

tests were performed, and statistical significance is defined as \*p < 0.05 and \*\*p < 0.01.



Figure S3. Levels of SARS-CoV-2 specific IgG and IgA in nasal samples evaluated in

- 383 Figure 3D.
- Levels of Anti-S1, Anti-S2, Anti-RBD, and Anti-Nucleocapsid IgG (A) and IgA (B) in the 4
- 385 selected nasal samples from each group used for NETosis assay. Two-tailed Mann-Whitney U
- tests were performed, and statistical significance is defined as \*p < 0.05.
- 387

# 388 **TABLES**

		Sal	iva		Serum			
	V0 (N = 14)	V1 (N = 17)	V2 (N = 13)	V3 (N = 4)	V0 (N = 19)	V1 (N = 23)	V2 (N = 20)	V3 (N = 6)
Age (month)								
Minimum	6.87	6.87	6.87	6.81	9.24	6.87	6.87	6.97
Median (IQR)	12.72 (2.2)	13.74 (15.4)	13.05 (29)	12.86 (10.7)	13.74 (29.8)	13.74 (15.6)	14.28 (29.4)	12.85 (26)
Maximum	55.53	55.53	55.53	48.46	55.53	55.53	55.53	48.46
Sex								
Female	7 (50%)	8 (47.1%)	6 (46.2%)	2 (50%)	8 (42.1%)	11 (47.8%)	10 (50%)	4 (66.7%)
Male	7 (50%)	9 (52.9%)	7 (53.8%)	2 (50%)	11 (57.9%)	12 (52.2%)	10 (50%)	2 (33.3%)
Race								
White	11 (78.6)	9 (52.9%)	8 (61.5%)	4 (100%)	12 (63.1%)	12 (52.2%)	12 (60%)	5 (83.3%)
Black/African American	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (4.3%)	0 (0%)	0 (0%)
Asian	0 (0%)	2 (11.8%)	1 (7.7%)	0 (0%)	3 (15.8%)	3 (13%)	3 (15%)	0 (0%)
Other/Unknown	3 (21.4)	6 (35.3)	4 (30.8%)	0 (0%)	4 (21.1%)	7 (30.4%)	5 (25%)	1 (16.7%)
Ethnicity								
Hispanic	0 (0%)	0 (0%)	0 (0%)	4 (100%)	0 (0%)	1 (4.3%)	0 (0%)	0 (0%)
Not Hispanic	9 (64.3%)	9 (52.9%)	8 (61.5%)	0 (0%)	13 (68.4%)	13 (56.5%)	13 (65%)	5 (83.3%)
Unknown	5 (35.7%)	8 (47.1%)	5 (38.5%)	0 (0%)	6 (31.6%)	9 (39.1%)	7 (35%)	1 (16.7%)
COVID-19 Vaccine Status								
Not vaccincated	14 (100%)	0 (0%)	0 (0%)	0 (0%)	19 (100%)	0 (0%)	0 (0%)	0 (0%)
Pfizer-BioNTech	0 (0%)	5 (29.4)	5 (38.5%)	4 (100%)	0 (0%)	15 (65.2%)	7 (35%)	6 (100%)
Moderna	0 (0%)	12 (70.6%)	8 (61.5%)	0 (0%)	0 (0%)	8 (34.8%)	13 (65%)	0 (0%)

389

**Table 1. Characteristics of participants in longitudinal cohort.** 

	Negative	Vaccine-only	Vaccine/Infection	Prior Infection
	(N = 23)	(N = 22)	(N = 22)	(N = 36)
Age (month)				
Minimum	5	8	3	2
Median (IQR)	24 (24)	18.5 (24)	29 (25)	25.5 (22)
Maximum	47	57	53	58
Sex				
Female	5 (21.7%)	9 (40.9%)	12 (54.5%)	17 (47.2%)
Male	18 (78.3%)	13 (59.1%)	10 (45.5%)	19 (52.8%)
Race				
White	6 (26.1%)	11 (50%)	7 (31.8%)	12 (33.3%)
Black/African American	3 (13%)	1 (4.5%)	3 (13.6%)	4 (11.1%)
Asian	2 (8.7%)	3 (13.6%)	0 (0%)	3 (8.3%)
Other/Unknown	12 (52.2%)	7 (31.8%)	12 (54.5%)	17 (47.2%)
Ethnicity				
Hispanic	5 (21.7%)	0 (0%)	6 (27.3%)	10 (27.8%)
Not Hispanic	12 (52.2%)	13 (59.1%)	8 (36.4%)	16 (44.4%)
Unknown	6 (26.1%)	9 (40.9%)	8 (36.4%)	10 (27.8%)
COVID-19 Vaccine Status				
Not vaccinated	23 (100%)	0 (0%)	0 (0%)	36 (100%)
Pfizer-BioNTech	0 (0%)	9 (40.9%)	9 (40.9%)	0 (0%)
Moderna	0 (0%)	9 (40.9%)	8 (36.4%)	0 (0%)
Not known	0 (0%)	4 (18.2%)	5 (22.7%)	0 (0%)

392

**Table 2. Characteristics of participants in emergency department convenience cohort.** 

# 395 References

- Mettelman RC, Allen EK, Thomas PG. Mucosal immune responses to infection and
   vaccination in the respiratory tract. Immunity 2022; 55:749–780.
- 2. Hassan AO, Kafai NM, Dmitriev IP, et al. A Single-Dose Intranasal ChAd Vaccine Protects
  Upper and Lower Respiratory Tracts against SARS-CoV-2. Cell **2020**; 183:169-184.e13.
- 3. Fröberg J, Gillard J, Philipsen R, et al. SARS-CoV-2 mucosal antibody development and
  persistence and their relation to viral load and COVID-19 symptoms. Nat Commun 2021;
  12:5621.
- 4. Sano K, Bhavsar D, Singh G, et al. SARS-CoV-2 vaccination induces mucosal antibody
  responses in previously infected individuals. Nat Commun 2022; 13:5135.
- 5. Bhavsar D, Singh G, Sano K, et al. Mucosal antibody responses to SARS-CoV-2 booster
  vaccination and breakthrough infection. mBio 2023; 14:e02280-23.
- 408 6. Nantel S, Sheikh-Mohamed S, Chao GYC, et al. Comparison of Omicron Breakthrough
- Infection Versus Monovalent SARS-CoV-2 Intramuscular Booster Reveals Differences in
   Mucosal and Systemic Humoral Immunity. Mucosal Immunol 2024;
- 7. Roubidoux EK, Brigleb PH, Vegesana K, et al. Utility of nasal swabs for assessing mucosal
  immune responses towards SARS-CoV-2. Sci Rep 2023; 13:17820.
- 8. Nziza N, Deng Y, Wood L, et al. Humoral profiles of toddlers and young children following
  SARS-CoV-2 mRNA vaccination. Nat Commun 2024; 15:905.
- 9. Norman M, Gilboa T, Ogata AF, et al. Ultrasensitive high-resolution profiling of early
  seroconversion in patients with COVID-19. Nat Biomed Eng 2020; 4:1180–1187.
- 417 10. Boribong BP, LaSalle TJ, Bartsch YC, et al. Neutrophil profiles of pediatric COVID-19 and
  418 multisystem inflammatory syndrome in children. Cell Rep Med 2022; 3:100848.
- 11. Loske J, Röhmel J, Lukassen S, et al. Pre-activated antiviral innate immunity in the upper
  airways controls early SARS-CoV-2 infection in children. Nat Biotechnol 2022; 40:319–324.
- 421 12. CDC COVID Data Tracker: Pediatric Seroprevalence. Available at:
- 422 <u>https://covid.cdc.gov/covid-data-tracker/#pediatric-seroprevalence</u>. Accessed 14 March 2024.
- 423 13. Spiekermann GM, Finn PW, Ward ES, et al. Receptor-mediated Immunoglobulin G
- Transport Across Mucosal Barriers in Adult Life. J Exp Med **2002**; 196:303–310.
- 425 14. Russell MW, Moldoveanu Z, Ogra PL, Mestecky J. Mucosal Immunity in COVID-19: A
- 426 Neglected but Critical Aspect of SARS-CoV-2 Infection. Front Immunol **2020**; 11:611337.

- 427 15. Bemark M, Angeletti D. Know your enemy or find your friend?—Induction of IgA at
  428 mucosal surfaces. Immunol Rev 2021; 303:83–102.
- 16. Havervall S, Marking U, Svensson J, et al. Anti-Spike Mucosal IgA Protection against
   SARS-CoV-2 Omicron Infection. New Engl J Med 2022;
- 431 17. Verheul MK, Kaczorowska J, Hofstee MI, et al. Protective mucosal SARS-CoV-2 antibodies
  432 in the majority of the general population in the Netherlands. Mucosal Immunol 2024;
- 18. Ellis S, Way R, Nel M, et al. Salivary IgA and vimentin differentiate in vitro SARS-CoV-2
  infection: a study of 290 convalescent COVID-19 patients. Mucosal Immunol 2023;
- 435 19. Mohanty T, Sjögren J, Kahn F, et al. A novel mechanism for NETosis provides antimicrobial
  436 defense at the oral mucosa. Blood **2015**; 126:2128–2137.
- 437 20. Hwang JW, Kim JH, Kim HJ, et al. Neutrophil extracellular traps in nasal secretions of
- 438 patients with stable and exacerbated chronic rhinosinusitis and their contribution to induce
- 439 chemokine secretion and strengthen the epithelial barrier. Clin Exp Allergy **2019**; 49:1306–1320.
- 21. Yonker LM, Boucau J, Regan J, et al. Virologic features of SARS-CoV-2 infection in
  children. J Infect Dis 2021; 224:jiab509-.
- 442 22. Yonker LM, Neilan AM, Bartsch Y, et al. Pediatric Severe Acute Respiratory Syndrome
- 443 Coronavirus 2 (SARS-CoV-2): Clinical Presentation, Infectivity, and Immune Responses. J
- 444 Pediatr **2020**; 227:45-52.e5.
- 23. Pilapitiya D, Wheatley AK, Tan H-X. Mucosal vaccines for SARS-CoV-2: triumph of hope
  over experience. eBioMedicine 2023; 92:104585.